Same-day dispatch
Order before 2pm ET — ships from Toronto
COA in every box
Batch-matched third-party certificate
Cold-pack shipped
Temperature-controlled packaging
Purity guarantee
Below spec? Replaced or refunded
Semaglutide
The World's Most Prescribed GLP-1 Peptide — Now Available for Research
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed by Novo Nordisk. As Ozempic and Wegovy, it is the world's second-best-selling prescription medicine with combined global sales of $26+ billion in 2024, growing at 40%+ year-over-year. In Canada, Ozempic (semaglutide injection) holds 95% market share among GLP-1 receptor agonists. Research has studied semaglutide for its effects on glucose homeostasis, appetite signaling, gastric emptying, and body composition in both diabetic and non-diabetic models.
- The most extensively published GLP-1 receptor agonist in the world
- Multiple large-scale phase 3 outcome trials (STEP, SUSTAIN, SELECT)
- 98.9% HPLC purity, endotoxin tested per batch
Vial size
10mg per vial · Lyophilized Powder · Ships same business day from Toronto
Questions about this batch? Text an agent at (905) 993-4764
14.9%
Mean weight reduction
STEP 1, 68 weeks, 2.4mg weekly
20%
MACE risk reduction
SELECT cardiovascular outcomes trial
~7 days
Half-life
Enables weekly-dosing study designs
Research benefits
Weight & Metabolic Research
Phase 3 trials demonstrated ~15% mean body weight reduction (STEP trials, NEJM 2021)
Glucose Homeostasis
Studied for GLP-1 receptor-mediated insulin secretion and glucagon suppression
Appetite Signaling
Researched for central nervous system effects on satiety and food intake regulation
Study findings
Summaries of published research on this compound. Findings are reported for scientific context only and do not constitute claims about this product.
STEP 1 — weight management
Mean change in body weight was -14.9% with semaglutide versus -2.4% with placebo over 68 weeks in 1,961 participants.
New England Journal of Medicine · 2021
SELECT — cardiovascular outcomes
Semaglutide reduced major adverse cardiovascular events by 20% versus placebo in 17,604 participants with overweight and established CVD.
New England Journal of Medicine · 2023
SUSTAIN 6 — type 2 diabetes
Semaglutide significantly reduced HbA1c and cardiovascular event rates in 3,297 participants over 104 weeks.
New England Journal of Medicine · 2016
What researchers report
Aggregated, anonymized observations from laboratories ordering this compound. Anecdotal and non-clinical.
The most-ordered metabolic reference standard in our catalog — commonly used as the control arm.
Researchers regularly note lot-to-lot HPLC consistency as the reason for repeat orders.
Frequently ordered alongside tirzepatide for head-to-head comparative protocols.
Technical specifications
| Form | Lyophilized Powder |
| Sequence | GLP-1 receptor agonist analogue |
| Molecular Weight | 4113.58 g/mol |
| Purity | ≥99% |
| Amount | 10mg per vial |
| Storage | Store at -20°C, protect from light |
| Shelf Life | 24 months (stored at -20°C) |
| COA | COA Available → View Lab Results |
Storage & reconstitution
Store lyophilized vial at -20°C, protected from light.
Reconstitute with bacteriostatic water; swirl, do not shake.
Refrigerate at 2–8°C and use within 30 days.
Research background
Semaglutide was first approved in 2017 and has since become the second-best-selling prescription medication in the world.
STEP clinical trials (NEJM 2021) demonstrated approximately 15% mean body weight reduction in non-diabetic populations over 68 weeks.
It dominates the Canadian GLP-1 market with 95% share, and the broader semaglutide portfolio grew over 40% year-over-year through 2024.
Frequently stacked with
Tirzepatide
Dual GLP-1/GIP agonist — Zepbound's active compound.
COA AvailableAvailable in 10mg · 15mg · 20mg · 30mg
Retatrutide
Triple GLP-1/GIP/Glucagon agonist — next-gen metabolic research.
COA AvailableAvailable in 5mg · 10mg · 20mg · 40mg
Third-party verified
ISO 17025 accredited lab — Batch TR-SEMA-2026-001
HPLC Purity
98.9%
Molecular Weight
✓ Verified
Endotoxin (LAL)
<1.0 EU/mg
Heavy Metals (ICP-MS)
✓ Pass
Semaglutide — frequently asked
How does semaglutide work?
It is a GLP-1 receptor agonist studied for effects on insulin secretion, gastric emptying and central appetite signalling.
What is the strongest published evidence?
STEP 1 (14.9% mean weight reduction at 68 weeks) and SELECT (20% MACE reduction) are the largest published trials.
Do you verify identity as well as purity?
Yes — mass spectrometry confirms molecular identity in addition to HPLC purity on every batch.
How fast does it ship?
Orders placed before 2pm ET ship the same business day from Toronto with tracked Canada-wide delivery, typically arriving in 1–3 business days. Cold-pack packaging is used on every shipment.
What if the purity doesn't match the COA?
Every batch is HPLC and mass-spec verified by an ISO 17025 accredited third-party lab, and the batch-matched COA ships with your order. If an independent test comes back below the stated purity, we replace the order or refund it in full.
Is this legal to purchase in Canada?
Yes — these compounds are sold strictly as in-vitro research chemicals for laboratory use. They are not for human or veterinary use, and it is the purchaser's responsibility to comply with applicable federal and provincial regulations.
Ready to add Semaglutide to your research?
≥99% HPLC-verified, endotoxin and heavy metals tested, batch-matched COA included. Ships same business day from Toronto.
Research Use Only Disclaimer
This product is sold exclusively for in-vitro research and laboratory use only. It is NOT intended for human or veterinary use, consumption, injection, or any clinical application. This product has not been evaluated by Health Canada, the FDA, or any other regulatory authority for safety or efficacy in humans or animals. Trinity makes no medical claims regarding this compound. Researchers must comply with all applicable federal, provincial/state, and local laws regarding the purchase, storage, and use of research compounds. By purchasing this product, you confirm you are a qualified researcher or licensed professional acting within the bounds of applicable law.